Heiko Graf
Helios Vogtland Klinikum Plauen(DE)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Estrogen and related hormone effects
Most-Cited Works
- → Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study(2014)171 cited
- → Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer(2019)20 cited
- → Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients(2019)8 cited
- → Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients(2020)8 cited
- → Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate – The ICE randomized clinical trial(2023)5 cited
- → 4003 ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32)(2009)4 cited
- → 4016 Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial(2009)3 cited
- → 1201 Intraoperative radiotherapy in elderly patients with breast cancer: long-term follow-up results of the prospective phase II trial TARGIT-E(2025)1 cited
- → Intraoperative radiotherapy in elderly patients with breast cancer: long-term follow-up results of the prospective phase II trial TARGIT-E(2025)
- → 109P Updated long-term overall survival of older adjuvant ibandronate-treated patients with intermediate- or high-risk early breast cancer compared with additional adjuvant capecitabine treatment: The ICE randomized clinical trial(2023)